Benedetto Maurizio Celesia
A5041785868- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS Research and Interventions
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Viral-associated cancers and disorders
- Pharmacological Effects and Toxicity Studies
- Lipoproteins and Cardiovascular Health
- Sex work and related issues
- Research on Leishmaniasis Studies
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Adolescent Sexual and Reproductive Health
- Vitamin D Research Studies
- Cardiovascular Disease and Adiposity
- Cerebrovascular and Carotid Artery Diseases
- Mosquito-borne diseases and control
Ospedale Garibaldi
2014-2024
University of Catania
2015-2024
Azienda di Rilievo Nazionale ed Alta Specializzazione
2012-2024
Weatherford College
2022
Office of Infectious Diseases
2020
University of Siena
2020
University of Rome Tor Vergata
2020
I.R.C.C.S. Oasi Maria SS
2018-2019
University of Turin
2019
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2018
Geriatric Patients Living with HIV/AIDS (GEPPO) is a new prospective observational multicentre cohort consisting of all the HIV-positive geriatric patients being treated at 10 clinics in Italy, and HIV-negative controls attending single clinic. The aim this analysis GEPPO was to compare prevalence risk factors individual non-communicable diseases (NCD), multi-morbidity (MM) polypharmacy (PP) amongst HIV positive negative enrolment into cohort. This cross-sectional study conducted between...
The intestinal microflora is not only involved in the digestion of nutrients, but also local immunity, forming a barrier against pathogenic microorganisms. derangement gut may lead to microbial translocation, defined as passage viable microorganisms or bacterial products (i.e., LPS, lipopeptides) from lumen mesenteric lymph nodes and other extraintestinal sites. most recent evidence suggests that translocation (MT) occur cirrhosis, early stage several liver diseases, including alcoholic...
Despite significant advances in the management of antiretroviral therapy (ART), leading to improved life expectancy for people living with HIV (PLWH), incidence non-AIDS-defining cancers, including breast cancer, has emerged as a critical concern. This review synthesizes current evidence on epidemiology cancer among HIV-infected individuals, highlighting potential an altered risk profile, earlier onset, and more advanced disease at diagnosis. It delves into molecular considerations...
Abstract Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through SCOLTA cohort revealed significant 1-year BMI treated dolutegravir (P = .004), raltegravir .0004), elvitegravir darunavir .0006), rilpivirine .029). correlated low baseline .002) older age .0007) Centers for Disease Control Prevention stages A/B, lower .005) CD4+ T-cell count .007) at enrollment stage C.
European guidelines recommend the routine offer of an HIV test in patients with a number AIDS-defining and non-AIDS conditions believed to share association HIV; so called indicator (IC). Adherence this guidance across Europe is not known. We audited testing behaviour accessing care for ICs. Participating centres reviewed case notes either 100 or all consecutive one year, presenting each following ICs: tuberculosis, non-Hodgkins lymphoma, anal cervical cancer, hepatitis B C oesophageal...
An unexpected excess in weight gain has recently been reported the course of dolutegravir (DTG) treatment. The aim present study was to investigate whether differs among different DTG-containing regimens.Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 December 2019 Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model compare change...
Since late December 2019, severe acute respiratory syndrome coronavirus 2 has spread across the world, which resulted in World Health Organization declaring a global pandemic. Coronavirus disease 2019 (COVID-19) presents highly variable spectrum with regard to severity of illness. Most infected individuals exhibit mild moderate illness (81%); however, 14% have serious and 5% develop distress (ARDS), requiring intensive care support. The mortality rate COVID-19 continues rise world. Data...
Introduction Little information is available on the efficacy and safety of dual combination ripivirine plus dolutegravir. This work aims at beginning to fill this gap. Methods All HIV-1 infected subjects treated with dolutegravir between October 2014 September 2015 in eight Italian centres were included an observational cohort. Data collected baseline weeks 4, 12, 24 48. Results One hundred thirty-two followed for a median months, mean 33 months. subject discontinued study drug week...
Currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside protease integrase strand transfer inhibitors). The study aimed to assess incidence clinical events death this population. This was cohort PWH from PRESTIGIO Registry documented 4DR virus. Burden disease defined as occurrence any new event including an AIDS-defining (ADE) or...
Background: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients. Objective: The primary objective is report 96-week virological suppression our cohort, assessing durability this strategy complicated situations. secondary describe safety and metabolic profile. Methods: All patients who had switched DTG RPV between October 1, 2014, September 30, 2015, were analyzed using a retrospective-prospective design, approved by...
GEPPO is a prospective observational multi-centric cohort including HIV-infected geriatric patients. We hypothesized that the may help characterize antiretroviral (ARV) prescribing criteria used in real life by Italian infectious disease (ID) physicians.This was cross-sectional study describing current ARV regimen HIV population (≥65 years). Antiretroviral strategies were categorized as follows: (i) multidrug regimens (MDRs), which comprised triple or mega ART combinations; (ii) less drug...
To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing standard regimen 2NRTI in virologically suppressed patients. ATLAS-M is 96 week open-label, randomized, non-inferiority (margin −12%) trial enrolling HIV-infected adults on 2NRTI, stable HIV-RNA <50 copies/mL CD4 counts >200 cells/mm3. At baseline, patients were randomized 1:1 or continue previous regimen. Here, we report data. The study was registered...
We aimed to investigate the effect of switching from tenofovir disoproxil fumarate (TDF) alafenamide (TAF) on hepatic safety and metabolic profile.Consecutive HIV patients, enrolled in Surveillance Cohort Long-term Toxicity Antiretrovirals/Antivirals (SCOLTA) project, TDF TAF were included. Changes baseline (T0) 6-month follow-up (T1) evaluated using paired t-test signed rank test.A total 190 patients switched had one visit. They 80% male, 74.2% at CDC stage A-B, 93.7% with undetectable...
[b]BACKGROUND[/b] Patients with HIV infection tend to have poor intensive care unit (ICU) outcomes; however, survival in the modern combination antiretroviral therapy (cART) era has markedly improved, but [i]Pneumocystis jirovecii[/i] pneumonia (PJP) still remains a preeminent cause of respiratory failure AIDS patients. Extracorporeal membrane oxygenation (ECMO) is an adapted cardiopulmonary bypass circuit for temporary life support patients not responding conventional treatment. [b]CASE...
The aim of this study was to explore weight gain in people with HIV (PWH) at least 65 years age who switch a DTG based regimen (DTG-s) vs. remaining INSTI-naive (INSTI-n) on stable ART.This longitudinal prospective PWH from the GEPPO cohort. At beginning observational period, participants were INSTI-naives (INSTI-n). During follow-up, they divided two groups: INSTI-n dolutegravir-switchers no further change ART. Body assessed baseline and last follow-up visit. Significant defined as an...